Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Dow
Boehringer Ingelheim
McKinsey
Merck

Last Updated: May 21, 2022

EDARBYCLOR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Edarbyclor patents expire, and when can generic versions of Edarbyclor launch?

Edarbyclor is a drug marketed by Azurity and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and eighteen patent family members in forty-three countries.

The generic ingredient in EDARBYCLOR is azilsartan kamedoxomil; chlorthalidone. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the azilsartan kamedoxomil; chlorthalidone profile page.

DrugPatentWatch® Generic Entry Outlook for Edarbyclor

Edarbyclor was eligible for patent challenges on February 25, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 4, 2030. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Drug patent expirations by year for EDARBYCLOR
Drug Prices for EDARBYCLOR

See drug prices for EDARBYCLOR

DrugPatentWatch® Estimated Generic Entry Opportunity Date for EDARBYCLOR
Generic Entry Date for EDARBYCLOR*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for EDARBYCLOR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
TakedaPhase 3

See all EDARBYCLOR clinical trials

US Patents and Regulatory Information for EDARBYCLOR

EDARBYCLOR is protected by five US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of EDARBYCLOR is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting EDARBYCLOR

Benzimidazole derivative and use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Benzimidazole derivative and use as a II receptor antagonist
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HYPERTENSION

Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Solid pharmaceutical composition
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HYPERTENSION

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Azurity EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-001 Dec 20, 2011 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Azurity EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-002 Dec 20, 2011 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Azurity EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-001 Dec 20, 2011 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for EDARBYCLOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Azurity EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-001 Dec 20, 2011 See Plans and Pricing See Plans and Pricing
Azurity EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-002 Dec 20, 2011 See Plans and Pricing See Plans and Pricing
Azurity EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-001 Dec 20, 2011 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for EDARBYCLOR

When does loss-of-exclusivity occur for EDARBYCLOR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 2883
Estimated Expiration: See Plans and Pricing

Australia

Patent: 09277455
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 0916847
Estimated Expiration: See Plans and Pricing

Canada

Patent: 32018
Estimated Expiration: See Plans and Pricing

Chile

Patent: 11000187
Estimated Expiration: See Plans and Pricing

China

Patent: 2164918
Estimated Expiration: See Plans and Pricing

Colombia

Patent: 41633
Estimated Expiration: See Plans and Pricing

Costa Rica

Patent: 110111
Estimated Expiration: See Plans and Pricing

Dominican Republic

Patent: 011000032
Estimated Expiration: See Plans and Pricing

Ecuador

Patent: 11010856
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 1170273
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 10385
Estimated Expiration: See Plans and Pricing

Israel

Patent: 0819
Estimated Expiration: See Plans and Pricing

Japan

Patent: 35491
Estimated Expiration: See Plans and Pricing

Patent: 11529444
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 11001150
Estimated Expiration: See Plans and Pricing

Morocco

Patent: 553
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 0948
Estimated Expiration: See Plans and Pricing

Peru

Patent: 110551
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 10385
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 1100871
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 110038145
Estimated Expiration: See Plans and Pricing

Taiwan

Patent: 1008915
Estimated Expiration: See Plans and Pricing

Tunisia

Patent: 11000045
Estimated Expiration: See Plans and Pricing

Ukraine

Patent: 3905
Estimated Expiration: See Plans and Pricing

Uruguay

Patent: 017
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EDARBYCLOR around the world.

Country Patent Number Title Estimated Expiration
Germany 602005016162 See Plans and Pricing
Japan H09183778 HETEROCYCLIC COMPOUND HAVING ANGIOTENSIN II ANTAGONISTIC ACTION See Plans and Pricing
Denmark 1718641 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for EDARBYCLOR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1718641 CA 2012 00013 Denmark See Plans and Pricing
1718641 2012/008 Ireland See Plans and Pricing PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209
1718641 C300525 Netherlands See Plans and Pricing PRODUCT NAME: AZILSARTAN MEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCHE AANVAARDBAAR ZOUT, IN HET BIJZONDER HET KALIUMZOUT; REGISTRATION NO/DATE: EU/1/11/734/001-011EU/1/11/735/001-011 2011071207
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
McKinsey
McKesson
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.